Kava

# Research Output: Kava (Piper methysticum)

PSX-0220 | Preparation (plant-based) | Generation Provenance: ac8e7a0b-753a-46e6-87c3-a875cc358594

---

## Botanical Identity

**Accepted binomial:** *Piper methysticum* G.Forst.
**Family:** Piperaceae
**Common names:** Kava, kava-kava, awa (Hawaiian), yaqona (Fijian), sakau (Pohnpeian), malok / malogu (parts of Vanuatu)

**First scientific description:** Georg Forster described and named *Piper methysticum* in 1786 in his publication *De Plantis Esculentis Insularum Oceani Australis Commentatio Botanica*, based on plant specimens collected during Captain James Cook's second voyage (1772–1775) to the South Pacific [Ref 47]. The specific epithet *methysticum* means "intoxicating" in Latin.

**Taxonomic notes:** *P. methysticum* is not a true wild species but represents a complex of sterile cultivars. Modern botanical research has established that all cultivated kava are somatic mutants or vegetatively propagated selections derived from the wild ancestor *Piper wichmanii* C.DC. (described 1910), which is native to Papua New Guinea, the Solomon Islands, and Vanuatu [Ref 47]. Because *P. methysticum* was formally named first (1786), it has taxonomic priority over *P. wichmanii*. Some authorities treat them as conspecific varieties. Kava plants are universally sterile (no viable seeds) and propagated exclusively by stem cuttings [Ref 33].

**Native range and cultivation:** Native range of the wild progenitor is Melanesia (PNG, Solomon Islands, Vanuatu). Cultivated kava (*P. methysticum*) has been spread across the Pacific over millennia by Austronesian peoples and is grown in Vanuatu, Fiji, Tonga, Samoa, Hawaii, the Federated States of Micronesia, and other Pacific Island groups. Vanuatu is considered the primary centre of origin and genetic diversity [Ref 33, Ref 47]. Kava is exclusively cultivated; no wild populations of *P. methysticum* exist. The plant requires warm, humid tropical conditions, well-drained volcanic soils, and partial shade.

**Cultivar classification — Noble vs. Non-noble:**
A critical distinction exists between "noble" and "non-noble" cultivars [Ref 15, Ref 33, Ref 36]:

- **Noble kava**: ~28–100+ named cultivars (Vanuatu Kava Act 2002 lists 28 approved for export) including Borogu, Palarasul, Melo Melo, and others. High kavain content; well-tolerated when consumed traditionally; preferred for regular use and medicinal applications.
- **Tudei (two-day) kava / non-noble**: Named for producing effects lasting two days with significant hangover-like effects (nausea, "kava hangover"). Higher dihydrokavain and dihydromethysticin content, lower kavain. Associated with greater adverse effects and implicated in hepatotoxicity concerns. Export prohibited under Vanuatu's Kava Act.
- **Wild kava (*P. wichmanii*)**: Not used for human consumption; progenitor species.

Borogu (Vanuatu) is specifically recommended in safety literature as the preferred cultivar for medicinal kava preparations [Ref 30, Ref 36].

**Morphological notes:** Erect perennial shrub, 1.5–3 m tall; large heart-shaped (cordate) alternate leaves with prominent veins; jointed stems with leaf nodes; inconspicuous flowers (small spikes); underground rhizomes and lateral roots constitute the medicinal preparation. Leaves are glossy and can measure 10–20 cm across. Misidentification risk: the plant is visually distinctive within its range; however, non-noble cultivars and tudei kava are morphologically similar to noble cultivars and cannot be reliably distinguished by appearance alone. Chemotype testing (HPLC or chemosensory evaluation) is required [Ref 15, Ref 30].

**Brief seed data vs. published sources:** The brief listed no botanical data. All botanical identity information here is sourced from published literature. The "type" field in the brief shows "preparation," which is appropriate — kava is consumed as a plant preparation (the beverage/extract), not as a raw plant part.

---

## Alkaloid / Cannabinoid Profile

**Primary active constituents:** Kavalactones (kavapyrones) — a class of substituted α-pyrones unique to the *Piper methysticum* plant. Six kavalactones account for approximately 96% of the total lipid resin and are the primary pharmacologically active compounds [Ref 4, Ref 33].

### Six Major Kavalactones (PubChem verified)

| Kavalactone | CID | Formula | MW | Notes |
|---|---|---|---|---|
| Kavain (K) | 5281565 | C₁₄H₁₄O₃ | 230.26 | Major anxiolytic; dominant in noble cultivars (~44% of extract); GABAA potentiator |
| Dihydrokavain (DHK) | 10220256 | C₁₄H₁₆O₃ | 232.27 | Saturated analog of kavain; achieves highest plasma Cmax despite lower extract content |
| Methysticin (M) | 5281567 | C₁₅H₁₄O₅ | 274.27 | Contains methylenedioxy group; more potent at CYP2C19 inhibition |
| Dihydromethysticin (DHM) | 88308 | C₁₅H₁₆O₅ | 276.28 | Saturated methysticin; significant CYP2C9/2C19 inhibition in vitro |
| Yangonin (Y) | 5281575 | C₁₅H₁₄O₄ | 258.27 | CB1 agonist activity suggested; fully conjugated α-pyrone |
| Desmethoxyyangonin (DMY) | 5273621 | C₁₄H₁₂O₃ | 228.24 | Smallest major kavalactone; CYP2C9/2C19 inhibitor at Ki 5-10 µM |

**Chemotype system:** Pacific Island kava producers use a six-digit "chemotype code" listing the six major kavalactones in order of decreasing concentration (e.g., 421356 for a kavain-dominant noble variety). Noble cultivars typically show codes beginning with 4 (kavain dominant) or 2 (DHK dominant) [Ref 33]. Kavain-dominant chemotypes are associated with more pleasant anxiolytic effects; DHK/DHM-dominant chemotypes with heavier sedation and more adverse effects.

**Kavalactone content by preparation:**
- Dried noble kava root/rhizome: 3–20% kavalactones by dry weight [Ref 33, Ref 51]
- Traditional aqueous beverage (per shell/serving): estimated 150–500 mg kavalactones, highly variable based on root quality, preparation method, and serving size [Ref 51]; **FLAG: this range is based on non-peer-reviewed commercial sources; no systematic published quantification study of traditional ceremony preparations was retrieved via API tools**
- Standardized pharmaceutical extract (e.g., WS1490): 70–240 mg kavalactones per dose, standardized to defined kavalactone content [Ref 25]
- Commercial dietary supplements: labeled kavalactone content highly variable; labeling accuracy concerns noted in quality control literature [Ref 33]

**Preparation-dependent constituent ratios:**
- **Aqueous (traditional) extraction**: Preferentially extracts more polar kavalactones; kavain and DHK are relatively more soluble in water. Aqueous extracts have lower total kavalactone yield than organic solvent extracts but may extract less flavokavain B [Ref 10, Ref 29]
- **Acetonic/ethanolic extraction**: Higher total kavalactone yield; also extracts lipophilic minor constituents including flavokavains A, B, C and other chalcones. Western commercial extracts predominantly used this method prior to hepatotoxicity concerns [Ref 10]
- **Noble cultivar aqueous extract from peeled roots/rhizomes**: Recommended formulation by safety consensus literature to minimize hepatotoxicity risk [Ref 36]

**Minor constituents of toxicological significance:**

*Flavokavains (chalcones):*
- Flavokavain A, B, and C: naturally occurring chalcones present in kava root [Ref 39]
- Flavokavain B: identified as the most hepatotoxic constituent in HepG2 cytotoxicity assays (Jhoo et al. 2006 [Ref 31]); induces GSH-sensitive oxidative stress via IKK/NF-κB and MAPK pathways; present in both root and peelings; content higher in non-noble cultivars
- Flavokavain A: potent anticancer properties (induces apoptosis in prostate/bladder cancer cells); also inhibits CYP in vitro (Niu et al. 2016 [Ref 20])
- The flavokavains review (Abu et al. 2013) gives comprehensive overview [Ref 39]

*Pipermethystine (alkaloid):*
- Found primarily in leaves and stem peelings (aerial parts), minimal in roots/rhizomes [Ref 34]
- 90% HepG2 cell death at 100 µM vs. negligible kavalactone cytotoxicity at same concentration (Nerurkar et al. 2004 [Ref 34])
- Disrupts mitochondrial function, decreases ATP, induces caspase-3-mediated apoptosis
- Presence in commercial supplements containing aerial plant material implicated in some hepatotoxicity cases [Ref 29, Ref 34]

*Potential contaminants:*
- Aflatoxins (B1, B2, G1, G2) and ochratoxin A from *Aspergillus* mold: hypothesized by Teschke et al. as possible hepatotoxin source in poorly dried/stored kava raw material [Ref 30]; **FLAG: background aflatoxin levels detected in kava samples but no direct causal evidence linking mold hepatotoxins to clinical kava hepatotoxicity cases has been published as of retrieved literature**
- Heavy metals, pesticides: hypothesized contamination risk in commercial products; no primary analytical study retrieved via API tools — **FLAG for human review**

---

## History & Ethnobotany

**Pre-contact traditional use:** Kava has been consumed in Pacific Island cultures for at least 3,000 years, possibly longer. Archaeological evidence and linguistic data suggest origin in Vanuatu or the broader Melanesian region [Ref 33]. The beverage is central to social, ceremonial, religious, and political life across Melanesia, Polynesia, and Micronesia. Traditional uses include:
- Social rituals: community gatherings, dispute resolution, welcoming guests
- Religious and spiritual ceremonies: communication with ancestors and deities
- Medicinal use: anxiety, insomnia, urinary complaints, pain relief, gonorrhea treatment
- Political contexts: chiefly ceremonies, treaty signings

**Preparation in Pacific cultures:** Traditionally, kava root was chewed by young men or women with good dental hygiene, mixed with water, and strained. Later methods substituted pounding with stones or mechanical grinding [Ref 33]. The resulting liquid (murky, tan-brown) is consumed from coconut shells. The chewing method was noted by early European explorers; it is now less common in many areas, replaced by stone pounding or blender preparation. The chewing method may alter kavalactone content through salivary amylase activity.

**Western discovery timeline:**
- 1772–1775: First European scientific observation during Cook's second voyage; Georg Forster collected specimens [Ref 47]
- 1786: Formal botanical description by G. Forster [Ref 47]
- Late 19th century: Kava introduced into European pharmacopoeias; used for urinary tract infections and nervous conditions
- 1860s–1890s: Several alkaloid/constituent investigation attempts; true kavalactone chemistry not resolved until 20th century
- 1960s–1980s: Modern phytochemical characterization of kavalactones; pharmacological activity studies begin
- 1990s: Commercial kava extracts (notably WS1490 acetonic extract) marketed in Germany and Europe for anxiety; sales reached top-10 herbal medicine status in Europe and North America before hepatotoxicity concerns [Ref 3]
- 1999–2000: First case reports of severe liver injury (Russmann 2001 [Ref 53]; Humberston 2003 [Ref 11])
- 2001–2003: Regulatory bans in Germany (2002), France, UK, Canada, Switzerland, Australia (initially) — approximately one dozen countries [Ref 34]
- 2002: Vanuatu Kava Act enacted, defining noble cultivar standards for export [Ref 36]
- 2002: Cochrane review (Pittler & Ernst [Ref 26]) affirmed kava's anxiolytic efficacy
- 2005–2015: Scientific debate over hepatotoxicity causality; multiple CIOMS/WHO reviews; German courts begin overturning the ban
- 2011: Teschke et al. propose Pacific kava paradox is not sustainable; aqueous extracts also implicated [Ref 9]
- 2011: Six-point standardization plan proposed [Ref 36]
- 2015: Kuchta et al. document German court rulings; KALM project underway [Ref 32]
- 2020: Sarris et al. publish major 16-week GAD RCT results [Ref 12]
- 2024 (June): Cologne Administrative Court definitively lifts German ban [Ref 45]
- 2025: Growing "kava bar" culture in USA (Florida, California, Pacific Coast); Economidis et al. 2025 global review published [Ref 49]

**Regulatory history (summary by jurisdiction):** See Legal Status section below.

*Note:* Traditional-use accounts constitute substantial evidence for kava's efficacy and safety profile in the traditional context but must be distinguished from the clinical evidence base. FLAG: sections on ceremonial/spiritual use rely exclusively on ethnographic and anthropological accounts, not controlled clinical data.

---

## Neuroscience & Mechanism

**Primary receptor targets of kavalactones:**

**1. GABAA Receptor Potentiation (confirmed direct)**
Kavain directly and positively modulates GABAA receptors at multiple subunit combinations (Chua et al. 2016 [Ref 37]). Using Xenopus oocyte two-electrode voltage clamp:
- Kavain potentiated all tested receptor subtypes regardless of subunit composition
- Effect was greater at α4β2δ than at α1β2γ2L GABAARs
- Effect was NOT blocked by flumazenil → does not act at the classical benzodiazepine binding site
- β3N265M point mutation (known to reduce anesthetic sensitivity) also diminished kavain potentiation → suggests shared binding region with anesthetics
- Downstream: decreased dACC GABA levels measured by ¹H-MRS after 8 weeks of kava in GAD patients (Savage 2023 [Ref 2]); decreased GABRR2 (GABA-A rho subunit gene) expression (Cribb 2023 [Ref 1])

**2. Voltage-Gated Sodium Channel Blockade**
Kavalactones (particularly kavain) block voltage-gated sodium channels, reducing neuronal excitability. This mechanism underlies local anesthetic and anticonvulsant properties (Singh & Singh 2002 [Ref 4]).

**3. Voltage-Dependent Calcium Channel Inhibition**
DHM and kawain reduce excitatory neurotransmitter release via calcium channel blockade. Demonstrated in hippocampal slice preparations: kawain and DHM reversibly reduced NMDA/Ca²⁺-channel-mediated field potentials in guinea pig hippocampal CA1/CA3 at 5–40 µmol/L (Walden et al. 1997 [Ref 5]).

**4. NMDA Receptor Antagonism**
Reduction of NMDA receptor-mediated hippocampal field potentials by kawain and DHM, with additive effects when combined (Walden 1997 [Ref 5]).

**5. MAO-B Inhibition**
Reversible inhibition of monoamine oxidase B by kavalactones, contributing to elevated dopamine and phenylethylamine levels (Sarris 2011 [Ref 44]).

**6. Monoamine Reuptake Inhibition**
Noradrenaline and dopamine reuptake inhibition documented for some kavalactones (Sarris 2011 [Ref 44]).

**7. Serotonergic Activity**
Some kavalactones and the kava extract have reported 5-HT1A receptor ligand activity; interaction with serotonergic system supported by additive effects with ipsapirone (5-HT1A agonist) in hippocampal preparations (Walden 1997 [Ref 5]).

**8. Cannabinoid System**
Yangonin has been reported to act as a CB1 receptor agonist in some literature (referenced in Bian 2020 [Ref 33]); **FLAG: primary supporting study not retrieved — requires further investigation**.

**Summary:** Kava's anxiolytic profile appears to result from a multi-target mechanism: direct GABAA potentiation (not benzodiazepine-site-mediated), sodium and calcium channel blockade reducing neuronal excitability, NMDA antagonism, MAO-B inhibition, and monoamine effects. This polypharmacology may explain both the clinical efficacy and the lack of complete cross-tolerance or identical adverse effect profile compared to benzodiazepines.

**Pharmacokinetics (Kanumuri et al. 2022 [Ref 40]; Mathews et al. 2005 [Ref 23]):**
- **Tmax:** 1–3 hours across major kavalactones after oral dosing
- **Cmax:** Despite kavain comprising ~44% of extract, dihydrokavain achieves highest plasma Cmax (173.5 ± 173.1 ng/mL) > kavain (112.0 ± 117.2 ng/mL) > dihydromethysticin (92.9 ± 73.4 ng/mL)
- **Half-life:** Approximately 9 hours for kavalactones and metabolites
- **Elimination:** Primarily urine (>90% within 72h for kawain); partially feces
- **Bioavailability:** Not formally quantified in humans from peer-reviewed data retrieved; in rat model, kava extract co-administration tripled kawain AUC (self-inhibition of CYP metabolism) (Mathews 2005 [Ref 23])
- **Metabolites:** Kavalactone metabolites identified in human urine as mercapturates (glutathione conjugates); reactive metabolite formation in vitro [Ref 29]

**CYP Enzyme Involvement:**
- **In vitro:** CYP2C9, CYP2C19, CYP2D6, CYP3A4 inhibited by kava extract and individual kavalactones. Ki values for CYP2C9 and CYP2C19 inhibition by methysticin, DHM, desmethoxyyangonin: 5–10 µM (Mathews 2005 [Ref 23])
- **In vivo (human, standard doses):**
  - CYP3A4: Not significantly inhibited by 14-day kava supplementation (Gurley 2008 [Ref 21])
  - CYP2D6: Not significantly inhibited by 14-day kava supplementation (Gurley 2008 [Ref 16])
  - Multiple CYPs (1A2, 2D6, 2E1, 3A4/5): Assessed in human volunteers with long-term kava supplementation (Gurley 2005 [Ref 17])
  - P-glycoprotein: No significant effect on digoxin pharmacokinetics (Gurley 2007 [Ref 22])
- **In vivo (rat):** Kava extract increased midazolam Cmax 4-fold and AUC 4-fold via intestinal CYP3A inhibition (Nascimento 2024 [Ref 19]); kava also increased P-gp substrate fexofenadine uptake 3.5-fold
- **Clinical interpretation:** Discrepancy between in vitro and human in vivo data; standard supplemental doses may not achieve in vivo inhibitory concentrations for CYP3A/2D6, but intestinal CYP3A inhibition possible at higher doses. Caution warranted with narrow therapeutic index drugs.

---

## Effects & Dose by Preparation

Plant articles use preparation-specific dose blocks. Dose data from clinical RCTs and traditional context sources are separated. **FLAG: Traditional beverage kavalactone content estimates are based on non-peer-reviewed industry sources; no peer-reviewed quantification study of traditional kava ceremony serving sizes was retrieved.**

---

### Preparation 1: Traditional Aqueous Beverage (Kava ceremony / kava bar)

**Preparation method:** Dried or fresh noble kava root/rhizome ground or pounded, mixed with cold-to-lukewarm water (hot water degrades kavalactones), kneaded and strained through fibrous cloth or plant fiber. Served in coconut shell ("bilo" in Fiji, "bilo" or "ipu" in Hawaii).

**Kavalactone content (estimated):** ~150–500 mg per shell (120–180 mL) depending on cultivar, root-to-water ratio, and preparation technique [Ref 51]. Noble kava root contains 3–20% kavalactones by dry weight [Ref 33].

- **Threshold dose:** ~60–100 mg kavalactones (mild relaxation, slight numbness in mouth)
- **Common range:** 150–300 mg kavalactones per serving (1–2 shells); most community sessions involve 2–4 shells
- **Heavy/ceremony range:** 400–800+ mg kavalactones in a full ceremony session
- **FLAG:** These dose estimates are derived from non-peer-reviewed sources; no systematic HPLC analysis of traditional serving sizes was retrieved via API tools. The range should be verified against published analytical chemistry studies.

**Onset:** 15–30 minutes | **Peak:** 1–2 hours | **Duration:** 2–4 hours (shorter than commercial supplements due to aqueous formulation)

**Subjective effects (from traditional accounts and pharmacological literature [Ref 4, Ref 33, Ref 44]):**
Mild to moderate sedation, muscle relaxation, sociability enhancement, mild euphoria, reduced anxiety, mild disinhibition, oral/perioral numbness (local anesthetic effect of kavain), some users report warming sensation in stomach. Does not impair cognition markedly at moderate doses.

---

### Preparation 2: Standardized Pharmaceutical Extract (Oral capsules/tablets)

**Examples:** WS1490 (acetonic extract, 70% kavalactones), LI 150 (ethanol extract); newer aqueous noble cultivar extracts per Sarris/KALM formulation.

- **Clinical therapeutic dose (anxiety):** 120 mg kavalactones twice daily (= 240 mg/day) as used in Sarris 2020 16-week GAD RCT [Ref 12]
- **Maximum recommended medicinal dose:** ≤250 mg kavalactones/day (Teschke six-point plan [Ref 36])
- **Acute study dose:** 180 mg kavalactones single dose (Sarris 2013 driving study [Ref 41]; Sarris 2012 acute effects [Ref 42])
- **Cochrane/meta-analysis effective dose range:** 70–210 mg kavalactones per dose [Ref 26, Ref 27]

**Onset:** 30–60 minutes | **Peak:** 1.5–2.5 hours (consistent with Tmax 1–3h [Ref 40]) | **Duration:** 4–8 hours

**Effects from RCT data:**
- Anxiolysis: HAM-A improvement significantly greater than placebo in meta-analyses (Pittler & Ernst 2000: WMD 9.69 on HAM-A [Ref 27])
- No driving impairment at 180 mg kavalactones vs. oxazepam 30 mg which caused significantly slower braking reaction time (Sarris 2013 [Ref 41])
- No significant reduction in alertness (vs. oxazepam which showed significant alertness reduction over time) [Ref 41]
- 8-week RCT (Sarris 2020 [Ref 12]): Efficacy for GAD confirmed in larger trial with aqueous noble cultivar extract

**Dose modifiers:** Cultivar chemotype significantly affects effects; kavain-dominant cultivars produce more pleasant anxiolytic effects while DHK/DHM-dominant produce heavier sedation; extract type (aqueous vs. organic solvent) alters constituent profile; user tolerance (regular Pacific kava drinkers exhibit reverse tolerance — require less to achieve effects); food intake (fatty meals may increase kavalactone bioavailability via lipophilic absorption).

---

### Preparation 3: Instant Kava Powder (Micronized/Instant)

Modern preparation: kava root finely milled, mixed directly into water without straining. Contains more plant particulates including potentially higher flavokavain content.

**FLAG:** No peer-reviewed dose-response data for instant/micronized kava was retrieved. Kavalactone content equivalent to traditional preparation per weight; bioavailability may differ. Anecdotal reports of more GI discomfort. Include with caveat.

---

## Safety & Toxicity

### Hepatotoxicity (Primary Safety Concern)

**Epidemiology:** Approximately 100 cases of liver injury reported globally, predominantly in Europe and the USA between 1999 and 2010, primarily associated with commercial organic solvent (acetonic/ethanolic) extracts [Ref 7, Ref 9]. A critical analysis of 26 cases suspected by regulatory agencies found causality difficult to firmly establish in most cases (Teschke 2008 [Ref 50]). Cases range from mild enzyme elevation to acute liver failure, liver transplantation (Becker 2019 [Ref 6]), and death. A tourist developed serious toxic liver disease after consumption of traditional Samoan kava ceremony preparations (Christl 2009 [Ref 38]).

**Mechanism — competing hypotheses (not definitively resolved [Ref 29]):**
1. **Flavokavain B toxicity**: HepG2 cytotoxicity studies identify flavokavain B as most potent hepatotoxic constituent; higher in non-noble cultivars and organic extracts; GSH-sensitive oxidative stress via IKK/NF-κB/MAPK (Jhoo 2006 [Ref 31])
2. **Pipermethystine from aerial parts**: 90% HepG2 cell death at 100 µM; mitochondrial apoptosis (Nerurkar 2004 [Ref 34]); commercial supplements using stems/peelings implicated
3. **Reactive metabolite formation**: Kavalactone metabolites form glutathione conjugates and mercapturate excretion products in vivo; in vitro GSH addition reduces cytotoxicity [Ref 29]
4. **CYP-mediated bioactivation**: Quinone formation or epoxide intermediates from kavalactone metabolism
5. **Mould hepatotoxins**: Aflatoxins/ochratoxin A from *Aspergillus* contamination of poorly-dried kava raw material (Teschke 2011 [Ref 30]; Rowe 2012 [Ref 28]); background aflatoxin levels detected but direct causal link not established
6. **Idiosyncratic reaction**: CYP2D6 polymorphism (poor metabolizers) as susceptibility factor — supported by Russmann 2001 [Ref 53]
7. **Alcohol potentiation**: Co-consumption of alcohol associated with worse outcomes (Russmann 2001 case [Ref 53])

**Pacific kava paradox (now contested):** Original hypothesis was that hepatotoxicity occurred only with organic extracts, not traditional aqueous preparations. This has been refuted by documented hepatotoxicity cases with traditional aqueous extracts in New Caledonia, Australia, and Germany (Teschke 2012 [Ref 9]). However, the rate of hepatotoxicity with traditional aqueous noble cultivar preparations in Pacific populations appears lower, possibly due to different constituent ratios and absence of aerial plant material.

**Risk factors for hepatotoxicity:**
- Organic solvent (acetonic/ethanolic) extracts vs. aqueous [Ref 10]
- Non-noble cultivars (higher flavokavain B, pipermethystine content) [Ref 15, Ref 30]
- Use of aerial plant material (leaves, stem peelings) [Ref 34]
- Concurrent alcohol use [Ref 53]
- Concurrent hepatotoxic medications
- CYP2D6 poor metabolizer phenotype [Ref 53]
- Mold-contaminated raw material [Ref 30]
- Pre-existing liver disease

**Incidence estimate:** Extremely rare with properly standardized noble cultivar aqueous extracts; the 100 case reports occurred across many years and significant global use [Ref 7]. WHO and German court assessments acknowledge the rare risk.

### Herb-Drug Interactions

**1. Alprazolam (and benzodiazepine class)**
*Mechanism:* Pharmacodynamic synergism — both act on GABAergic system (different sites but additive sedation/CNS depression)
*Evidence:* Case report of coma following combined kava + alprazolam use (Almeida & Grimsley 1996 [Ref 35]) — the specific case cited in the Psychedex seed database. This is a well-documented, seed-data-confirmed interaction.
*Severity:* Potentially life-threatening (coma reported)
*Recommendation:* Avoid concurrent use

**2. Alcohol**
*Mechanism:* Pharmacodynamic (additive CNS depression); possible pharmacokinetic potentiation of hepatotoxicity
*Evidence:* Singh 2005 review [Ref 3]; Russmann 2001 hepatotoxicity case involved alcohol co-consumption [Ref 53]
*Severity:* Moderate-high; both hepatotoxicity risk and sedation risk amplified

**3. CNS Depressants (sedatives, opioids, antihistamines, antipsychotics)**
*Mechanism:* Pharmacodynamic additive/synergistic CNS depression via multiple pathways
*Evidence:* Mechanistic basis from pharmacology literature [Ref 4, Ref 44]; clinical data limited to the alprazolam case
*Severity:* Clinically important; degree depends on agents

**4. CYP2C9/2C19 substrates (e.g., warfarin, phenytoin, omeprazole)**
*Mechanism:* In vitro CYP2C9/2C19 inhibition; Ki 5–10 µM for methysticin, DHM, desmethoxyyangonin (Mathews 2005 [Ref 23])
*Evidence:* In vitro pharmacokinetic mechanism; no clinical case reports retrieved confirming this interaction. Human in vivo studies at supplemental doses did not show significant CYP3A or CYP2D6 inhibition [Ref 16, Ref 21] but CYP2C9/2C19 not formally tested in humans.
*Severity:* Uncertain clinical magnitude — **FLAG: this interaction is supported by in vitro mechanistic data but no clinical case report or controlled human PK study was retrieved for CYP2C9/2C19. Flag for human review.**

**5. Hepatotoxic medications**
*Mechanism:* Additive hepatotoxicity risk
*Evidence:* Mechanistic rationale; not specifically documented in retrieved case reports
*Severity:* Contraindicated if pre-existing liver disease

**6. CYP3A4 substrates (midazolam, immunosuppressants, statins)**
*Mechanism:* Intestinal CYP3A inhibition demonstrated in rat (4x midazolam AUC increase, Nascimento 2024 [Ref 19]); not confirmed in standard-dose human studies (Gurley 2008 [Ref 21])
*Severity:* Possible at higher doses; low confidence in clinical significance at typical therapeutic doses

### Kava Dermopathy

A reversible skin condition (ichthyosis-like or pellagra-like scaly, dry, yellowish skin discoloration) associated with heavy chronic kava consumption, historically described in heavy Pacific kava users. Mechanism unclear — possibly related to niacin interference or kavalactone metabolites binding to skin proteins (reactive metabolite hypothesis) [Ref 4, Ref 29]. Reversible upon dose reduction or cessation. **FLAG: No primary dermatology study retrieved via API tools; documentation is from reviews only. The Teschke/Sarris cited reference to kava dermopathy in reviews should be verified against original dermatological literature.**

### Tolerance and Dependence

**Tolerance:** "Reverse tolerance" described in Pacific Islander kava communities — regular users report requiring less kava to achieve desired effects over time, opposite to typical pharmacological tolerance. Mechanism poorly understood. In clinical RCTs, 8–16 week use did not require dose escalation [Ref 12].

**Dependence:** At therapeutic/clinical doses, dependence risk is considered low; kava is described as "non-addictive" in clinical literature [Ref 39, Ref 44]. However, heavy traditional use in Pacific Island communities has been associated with physiological dependence. One severe withdrawal case documented (Bleifuss 2025 [Ref 18]): 45-year-old man using both kava and kratom heavily, presenting to ED with auditory and visual hallucinations, anxiety, insomnia, diffuse muscle jerking after cessation; initial buprenorphine (for suspected kratom withdrawal) insufficient; phenobarbital with significant improvement, transitioned to diazepam, discharged days later. This case implicates GABAergic dependence mechanism consistent with kava's pharmacology. **Note: patient was using both kava and kratom; isolated kava contribution to withdrawal is not definitively separated.**

**Withdrawal timeline (from Bleifuss 2025 [Ref 18]):** Symptoms onset within days of cessation of heavy use; included hallucinations, anxiety, insomnia, muscle jerking; duration of acute syndrome managed over several days. Data from a single case — insufficient to define population-level withdrawal characterization.

### Psychological Risks

- **Acute adverse reactions at therapeutic doses:** Mild GI upset most common; headache, dizziness, fatigue reported in RCTs [Ref 12]
- **High-dose acute sedation:** At high doses, significant sedation and motor impairment possible
- **Kava "hangover":** Particularly with tudei/non-noble cultivars — prolonged lethargy, nausea lasting up to 2 days [Ref 33]
- **Psychosis risk:** No documented cases of kava-induced psychosis found in retrieved literature; kava is not hallucinogenic at standard doses
- **Driving:** 180 mg kavalactones (therapeutic dose) does NOT impair simulated driving; oxazepam 30 mg does impair (Sarris 2013 [Ref 41])

### Contaminant/Adulterant Risk

- **Aerial plant material contamination** in commercial products: pipermethystine risk [Ref 34]; labeling inaccuracy documented
- **Non-noble cultivar substitution**: Flavokavain B risk [Ref 31]; visually identical to noble cultivars
- **Mold contamination (aflatoxins/ochratoxin A)**: Hypothesized but not causally established [Ref 30]
- **Kavalactone content variability**: Commercial products show significant variation in actual vs. labeled content [Ref 33]
- **Quality control gap**: No internationally harmonized kava product quality standard exists; Teschke 2011 [Ref 36] proposed Pan-Pacific quality control system but not yet implemented

### Vulnerable Populations

- **Pregnancy and lactation:** Contraindicated; insufficient safety data; some kavalactones may cross placenta [Ref 4] — **FLAG: no clinical study on kava in pregnancy retrieved; based on mechanistic concern and traditional-use caution**
- **Children and adolescents:** No data; contraindicated
- **Pre-existing liver disease:** Absolute contraindication
- **Heavy alcohol users:** Contraindicated (additive hepatotoxicity)
- **Psychiatric conditions:** Use caution; interaction with GABAergic medications; kava has efficacy for anxiety but not established for psychotic disorders
- **Hepatic CYP2D6 poor metabolizers:** Potentially increased hepatotoxicity risk [Ref 53]

---

## Harm Reduction

**Published risk reduction strategies (Teschke 2011 six-point plan [Ref 36]):**
1. Use only noble kava cultivars (e.g., Borogu from Vanuatu) at least 5 years old at harvest
2. Use only peeled and dried rhizomes and roots (not leaves, stems, or peelings)
3. Use aqueous (water-based) extraction only — not acetone or ethanol
4. Maximum daily dose: ≤250 mg kavalactones for medicinal use
5. Rigorous quality control testing of raw material (including mycotoxins)
6. Pan-Pacific quality control system with enforcement

**Testing and identification:** No validated point-of-care test for kava product quality; HPLC chemotyping of cultivar required. Consumers should source from suppliers providing HPLC kavalactone content certificates and noble cultivar documentation.

**Drug test consideration:** Regular kava use may cause false-positive results on amphetamine immunoassay urine drug screens (Madhavaram 2020 [Ref 43]). Consumers anticipating drug testing should inform testing parties. Confirmatory GC-MS testing will be negative for amphetamines.

**Cessation:** Heavy kava users should taper rather than abrupt cessation given the documented withdrawal case [Ref 18]. GABAergic withdrawal protocol (phenobarbital/benzodiazepine) may be indicated in severe cases. Medical supervision recommended for heavy, long-term users discontinuing use.

**Emergency:** Signs of liver injury (jaundice, abdominal pain, fatigue, dark urine) require immediate medical evaluation and cessation of kava use. Signs of severe withdrawal (hallucinations, severe anxiety, insomnia, tremors, muscle jerking) require emergency evaluation.

---

## Legal Status

**International Treaties:**
Kava (*Piper methysticum*) and kavalactones are NOT scheduled under any of the three principal UN drug control conventions: the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, or the 1988 UN Convention Against Illicit Traffic. No international treaty restriction applies to kava trade or consumption [Ref 52].

**United States:**
- Not a controlled substance under the Controlled Substances Act (CSA)
- Marketed and sold as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) 1994
- FDA does NOT consider kava Generally Recognized as Safe (GRAS) — 2020 FDA Scientific Memorandum
- FDA issued consumer advisory warnings about hepatotoxicity risk (2002, updated)
- Growing kava bar industry in Florida, California, and Pacific coast states; legal for commercial sale and consumption [Ref 46, Ref 52]

**Germany:**
- BfArM (Federal Institute for Drugs and Medical Devices) banned kava-containing pharmaceutical products in 2002
- First German administrative court rulings began overturning the ban circa 2013–2015; Kuchta 2015 documents these rulings [Ref 32]
- Administrative Court of Cologne definitively lifted the ban on June 18, 2024 [Ref 45]
- Kava may re-enter German market under January 2018 marketing authorizations with warning labels
- German court found ban was "inappropriate and even associated with an increased risk due to higher risk inherent to therapeutic alternatives" [Ref 32]

**France:**
- Outright ban on kava in any form (except certain approved homeopathic preparations) maintained as of 2024 [Ref 46]

**United Kingdom:**
- Banned; no reclassification as of retrieved data [Ref 46]

**Australia:**
- Therapeutics Goods Administration (TGA): kava approved as "listed medicine" (OTC) with ≤125 mg kavalactones per solid dose form; maximum daily dose ≤250 mg kavalactones
- Traditional kava import permitted for Pacific Island communities
- Medicinal kava products must comply with Australian Regulatory Guidelines for Complementary Medicines [Ref 46]

**Canada:**
- Previously restricted; natural health product regulations apply; available in some formulations [Ref 46]

**Netherlands, Indonesia, Japan, South Korea:**
- Prohibited in dietary supplements [Ref 46]

**Pacific Island nations:**
- Legal for traditional and cultural use throughout producing nations
- Vanuatu Kava Act 2002: governs noble cultivar standards; export restricted to approved cultivars
- Kava is a significant export commodity for Vanuatu, Fiji, Tonga — economic importance noted [Ref 49]

**FLAG — Low confidence jurisdictions:** EU member states other than Germany and France; South American countries (Brazil case report noted [Ref 6]); Southeast Asian non-producing countries. Legal status in these jurisdictions not verified in retrieved literature.

---

## Clinical Trials

Key registered trials (ClinicalTrials.gov):

| NCT ID | Title | Status | Phase | Condition | Sponsor |
|---|---|---|---|---|---|
| NCT02219880 | Kava for Treatment of Generalised Anxiety Disorder: KALM Double-Blind RCT | COMPLETED | Phase 4 | Generalized Anxiety Disorder | University of Melbourne |
| NCT03843502 | Phased Clinical Trial of Dietary Supplemental Kava: Pharmacokinetics | COMPLETED | Phase 1 | Pharmacokinetics | University of Florida |
| NCT05381025 | Kavalactones on Sleep and Cortisol in Healthy Special Forces Trainees | COMPLETED | N/A | Sleep | Thorne HealthTech, Inc. |
| NCT06177535 | Study of Oral Kavalactones Effect on Nurses | ACTIVE (not recruiting) | N/A | Stress | Mayo Clinic |
| NCT06213298 | Effect of Kava on Anxiety and Stress in Cancer Survivors | SUSPENDED | Early Phase 1 | Anxiety, Stress, Cancer | Masonic Cancer Center, Univ. Minnesota |
| NCT00009542 | Effects of Kava on Elimination of Caffeine and Dextromethorphan | COMPLETED | Phase 4 | Healthy | NIH Clinical Center |
| NCT03606655 | Kava on Metabolism of Nicotine and NNK | WITHDRAWN | Phase 1 | Tobacco | University of Florida |

**NCT02219880 is the landmark completed RCT** — Published results by Sarris et al. 2020 [Ref 12]; substudy publications include Savage 2023 neuroimaging [Ref 2] and Cribb 2023 gene expression [Ref 1]. Results confirmed kava efficacy for GAD over 16 weeks with aqueous noble cultivar extract.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. No community feedback items to evaluate.

---

## Gaps & Flags

**Safety-critical flags requiring human review:**

1. **FLAG — Dose values for traditional preparations (not peer-reviewed):** Kavalactone content per traditional shell (150–500 mg estimate) is derived from non-peer-reviewed commercial/industry sources. No HPLC-quantified study of traditional ceremony serving sizes was retrieved. Generation agent should present traditional dose range with explicit uncertainty.

2. **FLAG — Kava dermopathy primary literature not retrieved:** Described in multiple reviews as a known adverse effect of heavy chronic use but no primary dermatological case series or study was found via API tools. Classification as a known effect is based on review citations only.

3. **FLAG — Aflatoxin/mycotoxin contamination as hepatotoxicity cause:** Proposed by Teschke et al. but direct causal evidence not established in retrieved literature. Mold contamination hypothesis is plausible but unconfirmed.

4. **FLAG — CYP2C9/2C19 herb-drug interaction clinical significance:** In vitro Ki data suggests inhibition at 5–10 µM, but no controlled human PK study or clinical case report retrieved for drugs metabolized by CYP2C9/2C19 (e.g., warfarin, phenytoin). Not confirmed at standard therapeutic doses.

5. **FLAG — Pregnancy safety:** No clinical study; contraindication based on mechanistic concern and traditional-use avoidance; traditional-use accounts are the only evidence. Human review required.

6. **FLAG — Heavy metal/pesticide contamination in commercial products:** No primary analytical study retrieved. Possible risk from unregulated commercial sources but no direct evidence found.

7. **FLAG — Withdrawal characterization:** Only one case report (Bleifuss 2025 [Ref 18]), complicated by concurrent kratom use. Cannot define population-level kava withdrawal syndrome from single case. Isolated kava contribution not cleanly separated.

**Effect profile discrepancies:**

8. **Seed effect profile includes sexual arousal enhancement AND suppression simultaneously** — both listed. Published literature does not clearly address sexual arousal effects of kava. These effects may conflict with each other. Flag for human review; insufficient published literature to assign intensity/frequency.

9. **Transpersonal feelings, after-images, color enhancement, visual haze/noise** listed in seed profile — at standard doses, kava is not hallucinogenic or visually psychedelic in clinical literature. These effects, if they occur, would be at very high doses or in ceremonial contexts. Flag for human review.

10. **Dreaming enhancement** listed — No clinical study data retrieved supporting or refuting this. Traditional accounts may reference dream enhancement; flag as traditional-use-only evidence.

**Data absences:**

11. **No published LD50 data for humans** — toxicological profile based on case reports only.

12. **Kavalactone bioavailability in humans** — not formally quantified; only relative Tmax/Cmax available from Kanumuri 2022 [Ref 40].

13. **Seed data botanical fields all empty** — confirmed and populated in this research output from published sources.

14. **No dose data for kava tinctures or concentrated liquid extracts** — increasingly common commercial format; no peer-reviewed dose characterization found.

15. **Kava bar recreational use doses** — No systematic peer-reviewed study of doses consumed in modern kava bars was retrieved; consumption patterns in this context may exceed published medicinal dose ranges.

**Brief seed data inconsistencies:**

16. The brief characterizes this substance as "preparation" type, which is accurate (kava is a plant-derived preparation), but the generation agent should confirm whether the article is framed as a plant article or a preparation article. The botanical-overview and alkaloid-profile sections apply; standard plant article format is recommended.

17. The brief shows "emerging" characterization. This appears to be a DB classification that does not reflect the actual research depth — kava has extensive published literature including multiple Cochrane reviews and clinical RCTs. Generation agent should not treat this as a sparsely studied substance.